BAYLX, INC. Receives US FDA Clearance of COVID-19 IND Application For Umbilical Cord Tissue Mesenchymal Stem Cells Product

IRVINE, Calif.--(BUSINESS WIRE)--Baylx, Inc. (Baylx), a clinical-stage stem cell biopharmaceutical company focused on developing living stem cell products to address unmet medical needs, announced that the U.S. Food and Drug Administration (FDA) has cleared Baylx's Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) product in patients with COVID-19. Mesenchymal stem cells hold great promise to treat COVID-19 p

Click to view original post